参考文献/References:
[1] Hua W, Zhang LF, Wu YF, et al. Incidence of sudden cardiac death in China: analysis of 4 regional populations[J]. J Am Coll Cardiol, 2009, 54: 1110-1118.
[2] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2004, 44: 671-719.
[3] Uretsky BF, Sheahan RG.. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking?[J]. J Am Coll Cardiol, 1997, 30: 1589-1597.
[4] Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early after load reducing therapy study[J]. Ann Intern Med, 2001, 134: 451-458．
[5] Frommeyer G, Dechering DG, Zumhagen S, et al. Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience[J]. Clin Res Cardiol, 2016, 105: 89-93.
[6] Trivedi A, Knight BP. ICD therapy for primary prevention in hypertrophic cardiomyopathy[J]. Arrhythm Electrophysiol Rev, 2016, 5: 188-196.
[7] Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia[J]. N Engl J Med, 1996, 335: 1933-1940.
[8] van Rees JB, de Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices a systematic review of randomized clinical trials[J]. J Am Coll Cardiol, 2011, 58: 995-1000.
[9] Ziaeian B, Zhang Y, Albert NM, et al. Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification insights from the IMPROVE HF registry[J]. J Am Coll Cardiol, 2014, 64: 797-807.
[10] Gula LJ, Wells GA, Yee R, et al. A novel algorithm to assess risk of heart failure exacerbation using ICD diagnostics: validation from RAFT[J]. Heart Rhythm, 2014, 11: 1626-1631.
[11] 牟?凌， 李秋娟．埋藏式自动转律除颤起搏器安放术的护理体会[J]．介入放射学杂志， 2004， 13：271-271.
[12] Schwab JO, Bonnemeier H, Kleemann T, et al. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study[J]. Clin Res Cardiol, 2015, 104: 1021-1032．
[13] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017, 23: 628-651.
[14] Delise P, Allocca G, Sitta N, et al. Event rates and risk factors in patients with Brugada syndrome and no prior cardiac arrest: a cumulative analysis of the largest available studies distinguishing ICD-recorded fast ventricular arrhythmias and sudden death[J]. Heart Rhythm, 2014, 11: 252-258.
[15] Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete,nationwide cohort in Denmark[J]. Eur Heart J, 2014, 35: 1186–1194.
[16] 倪?钧， 沈卫峰．他汀类药物在冠心病介入中的应用进展[J]．
上海医学， 2003， 26：218-220.
[17] Anderson KP. Estimates of implantable cardioverter-defibrillator complications caveat emptor[J]. Circulation, 2009, 119: 1069-1071.
[18] 戴?剑， 曹恒献， 汤?涌， 等．射频消融治疗快速性心律失常的并发症及预防[J]．介入放射学杂志， 2004， 13：154．
[19] 张瑞波.?分析射频消融用于室性早搏触发特发性室性心动过速/心室颤动患者治疗中的临床效果[J]. 航空航天医学杂志， 2018， 29：417-419.
[20] 蔺刘亚， 马?会．射频消融治疗法对103例室性早搏冠心病患者疗效调查[J]．医学信息， 2013, 26：291.
[21] Jensen MK, Prinz C, Horstkotte D, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile[J]. Heart, 2013, 99: 1012-1017．
[22] Atoui M, Gunda S, Lakkireddy D, et al. Radiofrequency ablation to prevent sudden cardiac death[J]. Methodist Debakey Cardiovasc J, 2015, 11: 121-128.
[23] Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease.Multicenter unsustained tachycardia trial investigators[J]. N Engl J Med, 1999, 341: 1882-1890.
[24] Brinker JA. Implantable cardioverter-defibrillator lead failure: how weak is the link?[J]. Nat Clin Pract Cardiovasc Med, 2008, 5: 758-759.
[25] Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators[J]. Ann Intern Med, 2010, 153: 592-599.
[26] 吴清华， 程晓曙， 吴延庆， 等．植入型心律转复除颤器临床应用及随访观察[J]．介入放射学杂志， 2003， 12：164-165.
[27] 臧小彪， 陈?珂， 宋卫锋， 等.?心率变异性分析与首次行植入式心脏转复除颤器植入早期事件的关系[J]. 中华生物医学工程杂志， 2017， 23：219-223．
[28] 华?伟， 张?澍， 牛红霞， 等．植入型心律转复除颤器在心脏性猝死一级和二级预防中的应用——全国31家医院植入型心律转复除颤器植入适应证分析[J]．中华心律失常学杂志， 2010， 14：9-11.
[29] 梁义秀， 宿燕岗， 柏?瑾， 等．心脏性猝死一级与二级预防植入型心律转复除颤器患者临床特征单中心分析[J]．中华心律失常学杂志， 2012， 16：180-183．
[30] 戴?研， 陈柯萍， 华?伟， 等．植入型心律转复除颤器临床应用现状（20家医院注册研究）[J]．中华心律失常学杂志， 2017， 21：26-30．
[31] 殷?康， 华?伟， 丁立刚， 等．致心律失常右室心肌病患者植入埋藏式心律转复除颤器预防猝死长期随访结果[J]．中国循环杂志， 2017， 32：889-893．